Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma
To evaluate the efficacy and safety of a combined treatment with Sorafenib (Nexavar®) and pegylated interferon-α-2b (PegIntron®) in patients with malignant melanoma in stage IV.
Melanoma
DRUG: Sorafenib|DRUG: pegylated interferon α-2b
disease control rate (CR,PR,SD), 8 week staging
Best response, 12 months|Progression free survival (PFS), During active treatment|Overall survival, 48 week follow-up|Safety and tolerability of the combined treatment, During active treatment
This is a a prospective non-randomized, multicenter Phase II Study to evaluate the efficacy and safety of a combined treatment with Sorafenib (Nexavar®) and pegylated interferon-α-2b (PegIntron®) in patients with malignant melanoma in stage IV.

The investigators will determine disease control rate (CR,PR,SD) after 8 weeks of treatment with pegylated interferon- α-2b (3 µg/kg body weight s.c. once a week) combined with Sorafenib 2x 400 mg (2 tablets orally, twice daily)